CLINICAL_TRIALS
ClinicalTrials.gov record update
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02533700
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:47.531919+00:00
- Published At
- 2020-03-10T00:00:00+00:00
- Record Updated At
- 2020-03-10
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T Cell Lymphoma", "ALK-negative Anaplastic Large Cell Lymphoma", "Enteropathy Associated T Cell Lymphoma", "Subcutaneous Panniculitis Like T Cell Lymphoma", "Hepatosplenic T-cell Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-03-10"- protocolSection.identificationModule.nctId
"NCT02533700"- protocolSection.identificationModule.officialTitle
"CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL)"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.